Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.470 +0.060 (+2.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Theraptc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Esperion to Report Second Quarter 2023 Financial Results on August 1
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for Esperion Therapeutics's Future
Via Benzinga
Analyst Ratings for Esperion Therapeutics
Via Benzinga
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed... 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday
Piper Sandler boosted the price target for Accenture plc (NYSE: ACN) from $250 to $316. Piper Sandler analyst Arvind Ramnani upgraded the stock from Underweight to Neutral. Accenture shares rose 1.1%... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start breaking down the biggest pre-market stock movers for Thursday as we get ready for another busy day of trading! 
Via InvestorPlace
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Esperion Reports First Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
– Gibson Dunn Files Amended Complaint with Powerful New Evidence – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in JMP Securities Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That Are Preparing To Pump In Q2
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
From Esperion Therapeutics, Inc.
Via GlobeNewswire
7 Very Undervalued Penny Stocks to Buy in April 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option. 
Via InvestorPlace
Why SeaChange International Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That Preparing To Pump This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.